ArticleDrug delivery2021
Bioadhesive polymer/lipid hybrid nanoparticles as oral delivery system of raloxifene with enhancive intestinal retention and bioavailability.
Article in Drug delivery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Combined Nanoparticle-Based Delivery of Estrogens and Raloxifen in Postmenopausal Osteoporosis.Nanomaterials (Basel, Switzerland) · 2026Review
- Nanotechnology-Driven Therapeutic Potential of Raloxifene in Osteoporosis and Cancer: A Recent Review.Current pharmaceutical design · 2026Review
- Lipid nanoparticles: a promising tool for nucleic acid delivery in cancer immunotherapy.Medical oncology (Northwood, London, England) · 2025Review
- Adhesive lipophilic gels delivering rapamycin prevent oral leukoplakia from malignant transformation.Materials today. Bio · 2024Article
- Comprehensive Biosafety Profile of Carbomer-Based Hydrogel Formulations Incorporating Phosphorus Derivatives.Gels (Basel, Switzerland) · 2024Article
- The Role of Nanomedicine in Benign Gynecologic Disorders.Molecules (Basel, Switzerland) · 2024Review
- QbD-driven development of phospholipid-embedded lipidic nanocarriers of raloxifene: extensive in vitro and in vivo evaluation studies.Drug delivery and translational research · 2024Article
- Structure-Based Evaluation of Hybrid Lipid-Polymer Nanoparticles: The Role of the Polymeric Guest.Polymers · 2024Article
- Bone Targeting Nanoparticles for the Treatment of Osteoporosis.International journal of nanomedicine · 2024Review
- The application of nanoparticles in theranostic systems targeting breast cancer stem cells: current progress and future challenges.Stem cell research & therapy · 2023Review
- Review
- Article
- Orally administered intelligent self-ablating nanoparticles: a new approach to improve drug cellular uptake and intestinal absorption.Drug delivery · 2022Article
- Harnessing Lipid Polymer Hybrid Nanoparticles for Enhanced Oral Bioavailability of Thymoquinone: In Vitro and In Vivo Assessments.Polymers · 2022Article
- Preparation and Optimization of an Ultraflexible Liposomal Gel for Lidocaine Transdermal Delivery.Materials (Basel, Switzerland) · 2022Article
- Formulation of Piperine Nanoparticles: In Vitro Breast Cancer Cell Line and In Vivo Evaluation.Polymers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Raloxifene (RLX) is a second-generation selective estrogen receptor modulator used to treat osteoporosis in postmenopausal women. RLX fails to be developed into injectable dosage forms due to poor solubility. Although oral formulations are clinically available, the lower bioavailability (<2%) embarrasses the pharmaceutists. This work reported a bioadhesive nanosystem intended for oral delivery of RLX to enhance its oral bioavailability and address the formulation challenge. The bioadhesive nanosystem refers to polymer-lipid hybrid nanoparticles made up of Carbopol 940, glyceryl distearate, and TGPS. RLX was solidly encapsulated into bioadhesive nanoparticles (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.